Treatment of infections due to resistant staphylococcus aureus

Gregory M. Anstead, Jose Cadena, Heta Javeri

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter reviews data on the treatment of infections caused by drug-resistant Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This review covers findings reported in the English language medical literature up to January of 2013. Despite the emergence of resistant and multidrug-resistant S. aureus, we have seven effective drugs in clinical use for which little resistance has been observed: vancomycin, quinupristin- dalfopristin, linezolid, tigecycline, telavancin, ceftaroline, and daptomycin. However, vancomycin is less effective for infections with MRSA isolates that have a higher MIC within the susceptible range. Linezolid is probably the drug of choice for the treatment of complicated MRSA skin and soft tissue infections (SSTIs); whether it is drug of choice in pneumonia remains debatable. Daptomycin has shown to be non-inferior to either vancomycin or β-lactams in the treatment of staphylococcal SSTIs, bacteremia, and right-sided endocarditis. Tigecycline was also non-inferior to comparator drugs in the treatment of SSTIs, but there is controversy about whether it is less effective than other therapeutic options in the treatment of more serious infections. Telavancin has been shown to be non-inferior to vancomycin in the treatment of SSTIs and pneumonia, but has greater nephrotoxicity. Ceftaroline is a broad-spectrum cephalosporin with activity against MRSA; it is non-inferior to vancomycin in the treatment of SSTIs. Clindamycin, trimethoprim-sulfamethoxazole, doxycycline, rifampin, moxifloxacin, and minocycline are oral anti-staphylococcal agents that may have utility in the treatment of SSTIs and osteomyelitis, but the clinical data for their efficacy is limited. There are also several drugs with broad-spectrum activity against Gm-positive organisms that have reached the phase II and III stages of clinical testing that will hopefully be approved for clinical use in the upcoming years: oritavancin, dalbavancin, omadacycline, tedizolid, delafloxacin, and JNJ-Q2. Thus, there are currently many effective drugs to treat resistant S. aureus infections and many promising agents in the pipeline. Nevertheless, S. aureus remains a formidable adversary, and despite our deep bullpen of potential therapies, there are still frequent treatment failures and unfortunate clinical outcomes. The following discussion summarizes the clinical challenges presented by MRSA, the clinical experience with our current anti-MRSA antibiotics, and the gaps in our knowledge on how to use these agents to most effectively combat MRSA infections.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press
Pages259-309
Number of pages51
Volume1085
ISBN (Print)9781627036634
DOIs
StatePublished - 2014
Externally publishedYes

Publication series

NameMethods in Molecular Biology
Volume1085
ISSN (Print)10643745

Fingerprint

Soft Tissue Infections
Methicillin-Resistant Staphylococcus aureus
Staphylococcus aureus
Vancomycin
Linezolid
Skin
Infection
Pharmaceutical Preparations
Daptomycin
oritavancin
Pneumonia
Lactams
Minocycline
Clindamycin
Doxycycline
Sulfamethoxazole Drug Combination Trimethoprim
Osteomyelitis
Cephalosporins
Rifampin
Bacteremia

Keywords

  • ceftaroline
  • clindamycin
  • dalbavancin
  • daptomycin
  • delafloxacin
  • doxycycline
  • fosfomycin
  • fusidic acid
  • JNJ-Q2
  • linezolid
  • minocycline
  • MRSA
  • omadacycline
  • oritavancin
  • pristinamycin
  • rifampin
  • telavancin
  • tidezolid
  • tigecycline
  • trimethoprim-sulfamethoxazole
  • vancomycin

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Anstead, G. M., Cadena, J., & Javeri, H. (2014). Treatment of infections due to resistant staphylococcus aureus. In Methods in Molecular Biology (Vol. 1085, pp. 259-309). (Methods in Molecular Biology; Vol. 1085). Humana Press. https://doi.org/10.1007/978-1-62703-664-1-16

Treatment of infections due to resistant staphylococcus aureus. / Anstead, Gregory M.; Cadena, Jose; Javeri, Heta.

Methods in Molecular Biology. Vol. 1085 Humana Press, 2014. p. 259-309 (Methods in Molecular Biology; Vol. 1085).

Research output: Chapter in Book/Report/Conference proceedingChapter

Anstead, GM, Cadena, J & Javeri, H 2014, Treatment of infections due to resistant staphylococcus aureus. in Methods in Molecular Biology. vol. 1085, Methods in Molecular Biology, vol. 1085, Humana Press, pp. 259-309. https://doi.org/10.1007/978-1-62703-664-1-16
Anstead GM, Cadena J, Javeri H. Treatment of infections due to resistant staphylococcus aureus. In Methods in Molecular Biology. Vol. 1085. Humana Press. 2014. p. 259-309. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-62703-664-1-16
Anstead, Gregory M. ; Cadena, Jose ; Javeri, Heta. / Treatment of infections due to resistant staphylococcus aureus. Methods in Molecular Biology. Vol. 1085 Humana Press, 2014. pp. 259-309 (Methods in Molecular Biology).
@inbook{56091a7c57014816af9beb1f374ae34f,
title = "Treatment of infections due to resistant staphylococcus aureus",
abstract = "This chapter reviews data on the treatment of infections caused by drug-resistant Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This review covers findings reported in the English language medical literature up to January of 2013. Despite the emergence of resistant and multidrug-resistant S. aureus, we have seven effective drugs in clinical use for which little resistance has been observed: vancomycin, quinupristin- dalfopristin, linezolid, tigecycline, telavancin, ceftaroline, and daptomycin. However, vancomycin is less effective for infections with MRSA isolates that have a higher MIC within the susceptible range. Linezolid is probably the drug of choice for the treatment of complicated MRSA skin and soft tissue infections (SSTIs); whether it is drug of choice in pneumonia remains debatable. Daptomycin has shown to be non-inferior to either vancomycin or β-lactams in the treatment of staphylococcal SSTIs, bacteremia, and right-sided endocarditis. Tigecycline was also non-inferior to comparator drugs in the treatment of SSTIs, but there is controversy about whether it is less effective than other therapeutic options in the treatment of more serious infections. Telavancin has been shown to be non-inferior to vancomycin in the treatment of SSTIs and pneumonia, but has greater nephrotoxicity. Ceftaroline is a broad-spectrum cephalosporin with activity against MRSA; it is non-inferior to vancomycin in the treatment of SSTIs. Clindamycin, trimethoprim-sulfamethoxazole, doxycycline, rifampin, moxifloxacin, and minocycline are oral anti-staphylococcal agents that may have utility in the treatment of SSTIs and osteomyelitis, but the clinical data for their efficacy is limited. There are also several drugs with broad-spectrum activity against Gm-positive organisms that have reached the phase II and III stages of clinical testing that will hopefully be approved for clinical use in the upcoming years: oritavancin, dalbavancin, omadacycline, tedizolid, delafloxacin, and JNJ-Q2. Thus, there are currently many effective drugs to treat resistant S. aureus infections and many promising agents in the pipeline. Nevertheless, S. aureus remains a formidable adversary, and despite our deep bullpen of potential therapies, there are still frequent treatment failures and unfortunate clinical outcomes. The following discussion summarizes the clinical challenges presented by MRSA, the clinical experience with our current anti-MRSA antibiotics, and the gaps in our knowledge on how to use these agents to most effectively combat MRSA infections.",
keywords = "ceftaroline, clindamycin, dalbavancin, daptomycin, delafloxacin, doxycycline, fosfomycin, fusidic acid, JNJ-Q2, linezolid, minocycline, MRSA, omadacycline, oritavancin, pristinamycin, rifampin, telavancin, tidezolid, tigecycline, trimethoprim-sulfamethoxazole, vancomycin",
author = "Anstead, {Gregory M.} and Jose Cadena and Heta Javeri",
year = "2014",
doi = "10.1007/978-1-62703-664-1-16",
language = "English (US)",
isbn = "9781627036634",
volume = "1085",
series = "Methods in Molecular Biology",
publisher = "Humana Press",
pages = "259--309",
booktitle = "Methods in Molecular Biology",
address = "United States",

}

TY - CHAP

T1 - Treatment of infections due to resistant staphylococcus aureus

AU - Anstead, Gregory M.

AU - Cadena, Jose

AU - Javeri, Heta

PY - 2014

Y1 - 2014

N2 - This chapter reviews data on the treatment of infections caused by drug-resistant Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This review covers findings reported in the English language medical literature up to January of 2013. Despite the emergence of resistant and multidrug-resistant S. aureus, we have seven effective drugs in clinical use for which little resistance has been observed: vancomycin, quinupristin- dalfopristin, linezolid, tigecycline, telavancin, ceftaroline, and daptomycin. However, vancomycin is less effective for infections with MRSA isolates that have a higher MIC within the susceptible range. Linezolid is probably the drug of choice for the treatment of complicated MRSA skin and soft tissue infections (SSTIs); whether it is drug of choice in pneumonia remains debatable. Daptomycin has shown to be non-inferior to either vancomycin or β-lactams in the treatment of staphylococcal SSTIs, bacteremia, and right-sided endocarditis. Tigecycline was also non-inferior to comparator drugs in the treatment of SSTIs, but there is controversy about whether it is less effective than other therapeutic options in the treatment of more serious infections. Telavancin has been shown to be non-inferior to vancomycin in the treatment of SSTIs and pneumonia, but has greater nephrotoxicity. Ceftaroline is a broad-spectrum cephalosporin with activity against MRSA; it is non-inferior to vancomycin in the treatment of SSTIs. Clindamycin, trimethoprim-sulfamethoxazole, doxycycline, rifampin, moxifloxacin, and minocycline are oral anti-staphylococcal agents that may have utility in the treatment of SSTIs and osteomyelitis, but the clinical data for their efficacy is limited. There are also several drugs with broad-spectrum activity against Gm-positive organisms that have reached the phase II and III stages of clinical testing that will hopefully be approved for clinical use in the upcoming years: oritavancin, dalbavancin, omadacycline, tedizolid, delafloxacin, and JNJ-Q2. Thus, there are currently many effective drugs to treat resistant S. aureus infections and many promising agents in the pipeline. Nevertheless, S. aureus remains a formidable adversary, and despite our deep bullpen of potential therapies, there are still frequent treatment failures and unfortunate clinical outcomes. The following discussion summarizes the clinical challenges presented by MRSA, the clinical experience with our current anti-MRSA antibiotics, and the gaps in our knowledge on how to use these agents to most effectively combat MRSA infections.

AB - This chapter reviews data on the treatment of infections caused by drug-resistant Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This review covers findings reported in the English language medical literature up to January of 2013. Despite the emergence of resistant and multidrug-resistant S. aureus, we have seven effective drugs in clinical use for which little resistance has been observed: vancomycin, quinupristin- dalfopristin, linezolid, tigecycline, telavancin, ceftaroline, and daptomycin. However, vancomycin is less effective for infections with MRSA isolates that have a higher MIC within the susceptible range. Linezolid is probably the drug of choice for the treatment of complicated MRSA skin and soft tissue infections (SSTIs); whether it is drug of choice in pneumonia remains debatable. Daptomycin has shown to be non-inferior to either vancomycin or β-lactams in the treatment of staphylococcal SSTIs, bacteremia, and right-sided endocarditis. Tigecycline was also non-inferior to comparator drugs in the treatment of SSTIs, but there is controversy about whether it is less effective than other therapeutic options in the treatment of more serious infections. Telavancin has been shown to be non-inferior to vancomycin in the treatment of SSTIs and pneumonia, but has greater nephrotoxicity. Ceftaroline is a broad-spectrum cephalosporin with activity against MRSA; it is non-inferior to vancomycin in the treatment of SSTIs. Clindamycin, trimethoprim-sulfamethoxazole, doxycycline, rifampin, moxifloxacin, and minocycline are oral anti-staphylococcal agents that may have utility in the treatment of SSTIs and osteomyelitis, but the clinical data for their efficacy is limited. There are also several drugs with broad-spectrum activity against Gm-positive organisms that have reached the phase II and III stages of clinical testing that will hopefully be approved for clinical use in the upcoming years: oritavancin, dalbavancin, omadacycline, tedizolid, delafloxacin, and JNJ-Q2. Thus, there are currently many effective drugs to treat resistant S. aureus infections and many promising agents in the pipeline. Nevertheless, S. aureus remains a formidable adversary, and despite our deep bullpen of potential therapies, there are still frequent treatment failures and unfortunate clinical outcomes. The following discussion summarizes the clinical challenges presented by MRSA, the clinical experience with our current anti-MRSA antibiotics, and the gaps in our knowledge on how to use these agents to most effectively combat MRSA infections.

KW - ceftaroline

KW - clindamycin

KW - dalbavancin

KW - daptomycin

KW - delafloxacin

KW - doxycycline

KW - fosfomycin

KW - fusidic acid

KW - JNJ-Q2

KW - linezolid

KW - minocycline

KW - MRSA

KW - omadacycline

KW - oritavancin

KW - pristinamycin

KW - rifampin

KW - telavancin

KW - tidezolid

KW - tigecycline

KW - trimethoprim-sulfamethoxazole

KW - vancomycin

UR - http://www.scopus.com/inward/record.url?scp=84888367066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888367066&partnerID=8YFLogxK

U2 - 10.1007/978-1-62703-664-1-16

DO - 10.1007/978-1-62703-664-1-16

M3 - Chapter

SN - 9781627036634

VL - 1085

T3 - Methods in Molecular Biology

SP - 259

EP - 309

BT - Methods in Molecular Biology

PB - Humana Press

ER -